Cancer gene therapy - Current status in the clinics

Gene Therapy and Regulation

Volumn 2, Issue 3, 2004, Pages 219-274

  Pulkkanen, Kalevi J ^a,b   Sallinen, Hanna ^a,b   Tyynela, Kristiina ^a,b   Yla Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cancer; Clinical trials; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA 2 MICROGLOBULIN; CISPLATIN; E1A PROTEIN; FLUOROURACIL; HERPES SIMPLEX VIRUS THYMIDINE KINASE; HLA B7 ANTIGEN; INTERLEUKIN 2; ONYX 015; PROTEIN P53; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER; CANCER THERAPY; CHILL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; ECCHYMOSIS; FEVER; GENE THERAPY; GENE VECTOR; HUMAN; INJECTION PAIN; LIVER TOXICITY; MYALGIA; PRURITUS; REVIEW; SEIZURE;

ADENOVIRIDAE; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 7044267227     PISSN: 13889532     EISSN: None     Source Type: Journal    
DOI: 10.1163/1568558042457488     Document Type: Review

References (333)

1. Addison, C.L., Braciak, T., Ralston, R., Muller, W.J., Gauldie, J. and Graham, F.L. (1995). Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA, 92: 8522-8526.
2. Agarwala, S.S. and Kirkwood, J.M. (1996). Interferons in melanoma. Curr. Opin. Oncol., 8: 167-174.
3. Aghi, M., Hochberg, F. and Breakefield, X.O. (2000). Prodrug activation enzymes in cancer gene therapy. J. Gene Med., 2: 148-164.
4. Ahomadegbe, J.C., Barrois, M., Fogel, S., Le Bihan, M.L., Douc-Rasy, S., Duvillard, P., Armand, J.P. and Riou, G. (1995). High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 10: 1217-1227.
5. Ahrendt, S.A., Rashid, A., Chow, J.T., Eisenberger, C.F., Pitt, H.A. and Sidransky, D. (2000). p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J. Hepatobiliary. Pancreat. Surg., 7: 426-431.
6. Aisner, J. (1995). Current approach to malignant mesothelioma of the pleura. Chest, 107: 332S-344S.
7. Albert, M.L., Sauter, B. and Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392: 86-89.
8. Alemany, R., Balague, C. and Curiel, D.T. (2000). Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 18: 723-727.
9. Alvarez, R.D., Barnes, M.N., Gomez-Navarro, J., Wang, M., Strong, T.V., Arafat, W., Arani, R.B., Johnson, M.R., Roberts, B.L., Siegal, G.P. and Curiel, D.T. (2000b). A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res., 6: 3081-3087.
10. Alvarez, R.D., Gomez-Navarro, J., Wang, M., Barnes, M.N., Strong, T.V., Arani, R.B., Arafat, W., Hughes, J.V., Siegal, G.P. and Curiel, D.T. (2000a). Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther., 2: 524-530.
11. Amling, C.L., Thrasher, J.B., Frazier, H.A., Dodge, R.K., Robertson, J.E. and Paulson, D.F. (1994). Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J. Urol., 151: 31-35.
12. Antoine, F.S. (1988). First human gene transfer trial. J. Natl. Cancer Inst., 80: 1364-1365.
13. Asher, A.L., Mule, J.J., Kasid, A., Restifo, N.P., Salo, J.C., Reichert, C.M., Jaffe, G., Fendly, B., Kriegler, M. and Rosenberg, S.A. (1991). Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol., 146: 3227-3234.
14. Bajetta, E., Del Vecchio, M., Bernard-Marty, C., Vitali, M., Buzzoni, R., Rixe, O., Nova, P., Aglione, S., Taillibert, S. and Khayat, D. (2002). Metastatic melanoma: chemotherapy. Semin. Oncol., 29: 427-445.
15. Banchereau, J. and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature, 19;392: 245-252.
16. Banerjee, D. and Bertino, J.R. (2002). Myeloprotection with drug-resistance genes. Lancet Oncol., 3: 154-158.
17. Barrington, R.E., Subler, M.A., Rands, E., Omer, C.A., Miller, P.J., Hundley, J.E., Koester, S.K., Troyer, D.A., Bearss, D.J., Conner, M.W., Gibbs, J.B., Hamilton, K., Koblan, K.S., Mosser, S.D., O'Neill, T.J., Schaber, M.D., Senderak, E.T., Windle, J.J., Oliff, A. and Kohl, N.E. (1998). A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell Biol., 18: 85-92.
18. Barton, C.M., Staddon, S.L., Hughes, C.M., Hall, P.A., O'Sullivan, C., Kloppel, G., Theis, B., Russell, R.C., Neoptolemos, J., Williamson, R.C. et al. (1991). Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer, 64: 1076-1082.
19. Basu, A. (1993). The potential of protein kinase C as a target for anticancer treatment. Pharmacol. Ther., 59: 257-280.
20. Becker, C.M., Farnebo, F.A., Iordanescu, I., Behonick, D.J., Shih, M.C., Dunning, P., Christofferson, R., Mulligan, R.C., Taylor, G.A., Kuo, C.J. and Zetter, B.R. (2002). Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol. Ther., 1: 548-553.
21. Belldegrun, A. and deKemion, J.B. (1998). Renal Tumors. In: Campell's Urology, P.C. Walsh, A.B. Retik, E.D. Vaughan and A.J. Wein (Eds.), W.B. Saunders, Philadelphia, PA, pp. 2292-2318.
22. Belldegrun, A., Tso, C.L., Zisman, A., Naitoh, J., Said, J., Pantuck, A.J., Hinkel, A., deKemion, J. and Figlin, R. (2001). Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther., 20;12: 883-892.
23. Berchuck, A., Kohler, M.F., Marks, J.R., Wiseman, R., Boyd, J. and Bast, R.C. (1994). The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 170: 246-252.
24. Berger, A.C., Feldman, A.L., Gnant, M.F., Kruger, E.A., Sim, B.K., Hewitt, S., Figg, W.D., Alexander, H.R. and Libutti, S.K. (2000). The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J. Surg. Res., 91: 26-31.
25. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J. and Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284: 808-812.
26. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Hom, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A. and McCormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274: 373-376.
27. Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R. and Min, W. (1999). Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol., 17: 343-348.
28. Boehm, T., O'Reilly, M.S., Keough, K., Shiloach, J., Shapiro, R. and Folkman, J. (1998). Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. Biophys. Res. Commun., 252: 190-194.
29. Bogler, O., Huang, H.J., Kleihues, P. and Cavenee, W.K. (1995). The p53 gene and its role in human brain tumors. Glia, 15: 308-327.
30. Boon, T. and van der Bruggen, P. (1996). Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729.
31. Bos, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689.
32. Boulikas, T. (1998). An overview on gene therapy. In: Gene Therapy and Molecular Biology, T. Boulikas (Ed.), Gene Therapy Press, Palo Alto, CA, pp. 1-171.
33. Bouvet, M., Ellis, L.M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C.D., Fang, B., Lee, J.J. and Roth, J.A. (1998). Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res., 58: 2288-2292.
34. Boyle, J.O., Hakim, J., Koch, W., van der Riet, P., Hruban, R.H., Roa, R.A., Correo, R., Eby, Y.J., Ruppert, J.M. and Sidransky, D. (1993). The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 53: 4477-4480.
35. Brand, K. (2002). Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr. Gene Ther., 2: 255-271.
36. Brand, K., Baker, A.H., Perez-Canto, A., Possling, A., Sacharjat, M., Geheeb, M. and Arnold, W. (2000). Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res., 60: 5723-5730.
37. Brunori, M., Malerba, M., Kashiwazaki, H. and Iggo, R. (2001). Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol., 75: 2857-2865.
38. Buller, R.E., Runnebaum, I.B., Karlan, B.Y., Horowitz, J.A., Shahin, M., Buekers, T., Petrauskas, S., Kreienberg, R., Slamon, D. and Pegram, M. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther., 9: 553-566.
39. Burns, J.C., Friedmann, T., Driever, W., Burrascano, M. and Yee, J.K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA, 90: 8033-8037.
40. Cao, Y., O'Reilly, M.S., Marshall, B., Flynn, E., Ji, R.W. and Folkman, J. (1998). Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest., 101: 1055-1063.
41. Carmeliet, P. and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature, 407: 249-257.
42. Cavallo, F., Di Carlo, E., Butera, M., Verrua, R., Colombo, M.P., Musiani, P. and Forni, G. (1999). Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res., 59: 414-421.
43. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint, B., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Deist, F.L. and Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288: 669-672.
44. Chang, A.E., Aruga, A., Cameron, M.J., Sondak, V.K., Normolle, D.P., Fox, B.A. and Shu, S. (1997). Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol., 15: 796-807.
45. Chang, A.E., Li, Q., Bishop, D.K., Normolle, D.P., Redman, B.D. and Nickoloff, B.J. (2000). Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther., 11: 839-850.
46. Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. and Woo, S.L. (1994). Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA, 91: 3054-3057.
47. Chen, W.C., Liaw, C.C., Chuang, C.K., Chen, M.F., Chen, C.S., Lin, P.Y., Chang, P.L., Chu, S.H., Wu, C.T. and Hong, J.H. (2003). Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys., 56: 726-733.
48. Chesnoy, S. and Huang, L. (2000). Structure and function of lipid-DNA complexes for gene delivery. Annu. Rev. Biophys. Biomol. Struct., 29: 27-47.
49. Chhikara, M., Huang, H., Vlachaki, M.T., Zhu, X., Teh, B., Chiu, K.J., Woo, S., Berner, B., Smith, E.O., Oberg, K.C., Aguilar, L.K., Thompson, T.C., Butler, E.B. and Aguilar-Cordova, E. (2001). Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol. Ther., 3: 536-542.
50. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J.W., Cordon-Cardo, C., Yancopoulos, G.D. and DePinho, R.A. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature, 400: 468-472.
51. Claudio, P.P., Howard, C.M., Pacilio, C., Cinti, C., Romano, G., Minimo, C., Maraldi, N.M., Minna, J.D., Gelbert, L., Leoncini, L., Tosi, G.M., Hicheli, P., Caputi, M., Giordano, G.G. and Giordano, A. (2000). Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res., 60: 372-382.
52. Clayman, G.L., Frank, D.K., Bruso, P.A. and Goepfert, H. (1999). Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res., 5: 1715-1722.
53. Collins, T.M., Ash, D.V., Close, H.J. and Thorogood, J. (1988). An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchus. Clin. Radiol., 39: 284-286.
54. Colombo, M.P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F. and Parmiani, G. (1991). Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med., 173: 889-897.
55. Craig, C., Kim, M., Ohri, E., Wersto, R., Katayose, D., Li, Z., Choi, Y.H., Mudahar, B., Srivastava, S., Seth, P. and Cowan, K. (1998). Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene, 16: 265-272.
56. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 256: 1550-1552.
57. Cunningham, C.C., Holmlund, J.T., Schiller, J.H., Geary, R.S., Kwoh, T.J., Dorr, A. and Nemunaitis, J. (2000). A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res., 6: 1626-1631.
58. Dean, N.M. and McKay, R. (1994). Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 91: 11762-11766.
59. Dhanabal, M., Ramchandran, R., Waterman, M.J., Lu, H., Knebelmann, B., Segal, M. and Sukhatme, V.P. (1999). Endostatin induces endothelial cell apoptosis. J. Biol. Chem., 274: 11721-11726.
60. Dix, B.R., Edwards, S.J. and Braithwaite, A.W. (2001). Does the antitumor adenovirus ONYX-015/d11520 selectively target cells defective in the p53 pathway? J. Virol., 75: 5443-5447.
61. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V. and Wold, W.S. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol., 75: 3314-3324.
62. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543.
63. Dummer, R., Bergh, J., Karlsson, Y., Horowitz, J.A., Mulder, N.H., Huinink, D.T., Burg, G., Hofbauer, G. and Osanto, S. (2000). Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther., 7: 1069-1076.
64. Eastham, J.A., Chen, S.H., Sehgal, I., Yang, G., Timme, T.L., Hall, S.J., Woo, S.L. and Thompson, T.C. (1996). Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther., 7: 515-523.
65. Eder, J.P., Kantoff, P.W., Roper, K., Xu, G.X., Bubley, G.J., Boyden, J., Gritz, L., Mazzara, G., Oh, W.K., Arlen, P., Tsang, K.Y., Panicali, D., Schlom, J. and Kufe, D.W. (2000). A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res., 6: 1632-1638.
66. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D. and Eaves, C. (2002). Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther., 5: 352-359.
67. Fakhrai, H., Shawler, D.L., Gjerset, R., Naviaux, R.K., Koziol, J., Royston, I. and Sobol, R.E. (1995). Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther., 6: 591-601.
68. Faria, M., Spiller, D.G., Dubertret, C., Nelson, J.S., White, M.R., Scherman, D., Helene, C. and Giovannangeli, C. (2001). Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat. Biotechnol., 19: 40-44.
69. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simons, J.W., Karasuyama, H., Vogelstein, B. and Frost, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403.
70. Federico, M. (1999). Lentiviruses as gene delivery vectors. Curr. Opin. Biotechnol., 10: 448-453.
71. Finke, S., Trojaneck, B., Moller, P., Schadendorf, D., Neubauer, A., Huhn, D. and Schmidt-Wolf, I.G. (1997). Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. Cancer Gene Ther., 4: 260-268.
72. Folkman, J. (1996). Fighting cancer by attacking its blood supply. Sci. Am., 275: 150-154.
73. Fong, Y., Cohen, A.M., Fortner, J.G., Enker, W.E., Turnbull, A.D., Coit, D.G., Marrero, A.M., Prasad, M., Blumgart, L.H. and Brennan, M.F. (1997). Liver resection for colorectal metastases. J. Clin. Oncol., 15: 938-946.
74. Frank, D.K., Frederick, M.J., Liu, T.J. and Clayman, G.L. (1998). Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin. Cancer Res., 4: 2521-2528.
75. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D. and Kim, J.H. (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333.
76. Freytag, S.O., Khil, M., Stricker, H., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E. and Kim, J.H. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res., 62: 4968-4976.
77. Frisch, S.M. and Dolter, K.E. (1995). Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res., 55: 5551-5555.
78. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., McDonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K. and Kyritsis, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12.
79. Fujii, S., Huang, S., Fong, T.C., Ando, D., Burrows, F., Jolly, D.J., Nemunaitis, J. and Hoon, D.S. (2000). Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther., 7: 1220-1230.
80. Fyfe, G., Fisher, R.I., Rosenberg, S.A., Sznol, M., Parkinson, D.R. and Louie, A.C. (1995). Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688-696.
81. Gahery-Segard, H., Molinier-Frenkel, V., Le Boulaire, C., Saulnier, P., Opolon, P., Lengagne, R., Gautier, E., Le Cesne, A., Zitvogel, L., Venet, A., Schatz, C., Courtney, M., Le Chevalier, T., Tursz, T., Guillet, J.G. and Farace, F. (1997). Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest., 100: 2218-2226.
82. Galanis, E., Hersh, E.M., Stopeck, A.T., Gonzalez, R., Burch, P., Spier, C., Akporiaye, E.T., Rinehart, J.J., Edmonson, J., Sobol, R.E., Forscher, C., Sondak, V.K., Lewis, B.D., Unger, E.C., O'Driscoll, M., Selk, L. and Rubin, J. (1999). Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J. Clin. Oncol., 17: 3313-3323.
83. Galderisi, U., Cascino, A. and Giordano, A. (1999). Antisense oligonucleotides as therapeutic agents. J. Cell Physiol., 181: 251-257.
84. Ganly, I., Kim, D., Eckhardt, G., Rodriguez, G.I., Soutar, D.S., Otto, R., Robertson, A.G., Park, O., Gulley, M.L., Heise, C., Von Hoff, D.D., Kaye, S.B. and Eckhardt, S.G. (2000). A phase I study of Onyx-015, an EIB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 6: 798-806.
85. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R. and Gilboa, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172: 1217-1224.
86. Gleich, L.L., Gluckman, J.L., Armstrong, S., Biddinger, P.W., Miller, M.A., Balakrishnan, K., Wilson, K.M., Saavedra, H.I. and Stambrook, P.J. (1998). Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch. Otolaryngol. Head Neck Surg., 124: 1097-1104.
87. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M. and Pardoll, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254: 713-716.
88. Gomella, L.G., Mastrangelo, M.J., McCue, P.A., Maguire, H.C., Mulholland, S.G. and Lattime, E.C. (2001). Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol., 166: 1291-1295.
89. Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De Cicco, C., Fiorenza, M., Gatti, M., Caliceti, P. and Paganelli, G. (2002). Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer, 86: 207-212.
90. Greten, T.F. and Jaffee, E.M. (1999). Cancer vaccines. J. Clin. Oncol., 17: 1047-1060.
91. Grill, J., van Beusechem, V.W., van der Valk, P., Dirven, C.M., Leonhart, A., Pherai, D.S., Haisma, H.J., Pinedo, H.M., Curiel, D.T. and Gerritsen, W.R. (2001). Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res., 7: 641-650.
92. Griscelli, F., Opolon, P., Saulnier, P., Mami-Chouaib, F., Gautier, E., Echchakir, H., Angevin, E., Le Chevalier, T., Bataille, V., Squiban, P., Tursz, T. and Escudier, B. (2003). Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Therapy, 10: 386-395.
93. Gurnani, M., Lipari, P., Dell, J., Shi, B. and Nielsen, L.L. (1999). Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol., 44: 143-151.
94. Haas, G.P., Solomon, D. and Rosenberg, S.A. (1990). Tumor-infiltrating lymphocytes from nonrenal urological malignancies. Cancer Immunol. Immunother., 30: 342-350.
95. Habib, N.A., Sarraf, C.E., Mitry, R.R., Havlik, R., Nicholls, J., Kelly, M., Vernon, C.C., Gueret-Wardle, D., El Masry, R., Salama, H., Ahmed, R., Michail, N., Edward, E. and Jensen, S.L. (2001). E1B-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther., 12: 219-226.
96. Haddada, H., Ragot, T., Cordier, L., Duffour, M.T. and Perricaudet, M. (1993). Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum. Gene Ther., 4: 703-711.
97. Haisma, H.J., Pinedo, H.M., Rijswijk, A., der Meulen-Muileman, I., Sosnowski, B.A., Ying, W., Beusechem, V.W., Tillman, B.W., Gerritsen, W.R. and Curiel, D.T. (1999). Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Therapy, 6: 1469-1474.
98. Haisma, H.J., Grill, J., Curiel, D.T., Hoogeland, S., van Beusechem, V.W., Pinedo, H.M. and Gerritsen, W.R. (2000). Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther., 7: 901-904.
99. Hall, S.J., Mutchnik, S.E., Chen, S.H., Woo, S.L. and Thompson, T.C. (1997). Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int. J. Cancer, 70: 183-187.
100. Hallenbeck, P.L., Chang, Y.N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S. and Chiang, Y.L. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 10: 1721-1733.
101. Hamid, O., Varterasian, M.L., Wadler, S., Hecht, J.R., Benson, A., Galanis, E., Uprichard, M., Omer, C., Bycott, P., Hackman, R.C. and Shields, A.F. (2003). Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol., 21: 1498-1504.
102. Hasenburg, A., Tong, X.W., Rojas-Martinez, A., Nyberg-Hoffman, C., Kieback, C.C., Kaplan, A., Kaufman, R.H., Ramzy, I., Aguilar-Cordova, E. and Kieback, D.G. (2000). Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther., 7: 839-844.
103. Hasenburg, A., Tong, X.W., Fischer, D.C., Rojas-Martinez, A., Nyberg-Hoffman, C., Kaplan, A.L., Kaufman, R.H., Ramzy, I., Aguilar-Cordova, E. and Kieback, D.G. (2001). Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol., 83: 549-554.
104. Hawkins, D.S., Demers, G.W. and Galloway, D.A. (1996). Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898.
105. Hecht, J.R., Bedford, R., Abbruzzese, J.L., Lahoti, S., Reid, T.R., Soetikno, R.M., Kirn, D.H. and Freeman, S.M. (2003). A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res., 9: 555-561.
106. Heideman, D.A., Snijders, P.J., Craanen, M.E., Bloemena, E., Meijer, C.J., Meuwissen, S.G., van Beusechem, V.W., Pinedo, H.M., Curiel, D.T., Haisma, H.J. and Gerritsen, W.R. (2001). Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther., 8: 342-351.
107. Hejna, M., Pruckmayer, M. and Raderer, M. (1998). The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur. J. Cancer, 34: 977-986.
108. Helene, C., Garestier, T., Giovannageli, C. and Sun, J. (1998). Sequence-specific control of gene expression by antigene and clamp oligonucleotides. In: Gene therapy and molecular biology, T. Boulikas (Ed.), Gene Therapy Press, Palo Alto, CA, pp. 467-474.
109. Hemminki, A. (2002). From molecular changes to customised therapy. Eur. J. Cancer, 38: 333-338.
110. Herbst, R.S., Dang, N.H. and Skarin, A.T. (1997). Chemotherapy for advanced non-small cell lung cancer. Hematol. Oncol. Clin. North Am., 11: 473-517.
111. Herbst, R.S. (2003). Dose-comparative monotherapy trials of ZD 1839 in previously treated non-small cell lung cancer patients. Semin. Oncol., 30: 30-38.
112. Herman, J.R., Adler, H.L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., Timme, T.L., Wheeler, T.M., Thompson, T.C. and Scardino, P.T. (1999). In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther., 10: 1239-1249.
113. Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T. and Blankenstein, T. (1993). Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res., 53: 714-716.
114. Hodge, J.W., Schlom, J., Donohue, S.J., Tomaszewski, J.E., Wheeler, C.W., Levine, B.S., Gritz, L., Panicali, D. and Kantor, J.A. (1995). A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int. J. Cancer, 63: 231-237.
115. Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R. and Harris, C.C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3555.
116. Holt, J.T., Thompson, M.E., Szabo, C., Robinson-Benion, C., Arteaga, C.L., King, M.C. and Jensen, R.A. (1996). Growth retardation and tumour inhibition by BRCA1. Nat. Genet., 12: 298-302.
117. Hoover, H.C., Brandhorst, J. S., Peters, L.C., Surdyke, M.G., Takeshita, Y., Madariaga, J., Muenz, L.R. and Hanna, M.G. (1993). Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol., 11: 390-399.
118. Hortobagyi, G.N. (1998). Treatment of breast cancer. N. Engl. J. Med., 339: 974-984.
119. Hortobagyi, G.N. (2000). Developments in chemotherapy of breast cancer. Cancer, 88: 3073-3079.
120. Hortobagyi, G.N., Ueno, N.T., Xia, W., Zhang, S., Wolf, J.K., Putnam, J.B., Weiden, P.L., Willey, J.S., Carey, M., Branham, D.L., Payne, J.Y., Tucker, S.D., Bartholomeusz, C., Kilbourn, R.G., De Jager, R.L., Sneige, N., Katz, R.L., Anklesaria, P., Ibrahim, N.K., Murray, J.L., Theriault, R.L., Valero, V., Gershenson, D.M., Bevers, M.W., Huang, L., Lopez-Berestein, G. and Hung, M.C. (2001). Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J. Clin. Oncol., 19: 3422-3433.
121. Hoshida, T., Sunamura, M., Duda, D.G., Egawa, S., Miyazaki, S., Shineha, R., Hamada, H., Ohtani, H., Satomi, S. and Matsuno, S. (2002). Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas, 25: 111-121.
122. Huang, A.Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264: 961-965.
123. Hui, K.M., Ang, P.T., Huang, L. and Tay, S.K. (1997). Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Therapy, 4: 783-790.
124. Hunter, W.D., Martuza, R.L., Feigenbaum, F., Todo, T., Mineta, T., Yazaki, T., Toda, M., Newsome, J.T., Platenberg, R.C., Manz, H.J. and Rabkin, S.D. (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol., 73: 6319-6326.
125. Ikeda, T., Yoshinaga, K., Suzuki, A., Sakurada, A., Ohmori, H. and Horii, A. (2000). Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol. Rep., 7: 567-570.
126. Immonen, A., Vapalahti, M., Tyynela, K., Hurskainen, H., Sandmair, A., Vanninen, R., Langford, G., Murray, N. and Yla-Herttuala, S. (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther., in press.
127. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K. and Pehamberger, H. (2000). Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 356: 1728-1733.
128. Jemal, A., Thomas, A., Murray, T. and Thun, M. (2002). Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47.
129. Kanerva, A., Wang, M., Bauerschmitz, G.J., Lam, J.T., Desmond, R.A., Bhoola, S.M., Barnes, M.N., Alvarez, R.D., Siegal, G.P., Curiel, D. and Hemminki, A. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther., 5: 695-704.
130. Kaptein, L.C., Greijer, A.E., Valerio, D. and van Beusechem, V.W. (1997). Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene Therapy, 4: 172-176.
131. Kass, E., Parker, J., Schlom, J. and Greiner, J.W. (2000). Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine, 12: 960-971.
132. Kauczor, H.U., Schuler, M., Heussel, C.P., von Weymarn, A., Bongartz, G., Rochlitz, C., Huber, C. and Thelen, M. (1999). CT-guided intratumoral gene therapy in non-small-cell lung cancer. Eur. Radiol., 9: 292-296.
133. Kemeny, N. and Fata, F. (1999). Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J. Hepatobiliary. Pancreat. Surg., 6: 39-49.
134. Khan, M.A., Carducci, M.A. and Partin, A.W. (2003). The evolving role of docetaxel in the management of androgen independent prostate cancer. J. Urol., 170: 1709-1716.
135. Khorana, A.A., Rosenblatt, J.D., Sahasrabudhe, D.M., Evans, T., Ladrigan, M., Marquis, D., Rosell, K., Whiteside, T., Phillippe, S., Acres, B., Slos, P., Squiban, P., Ross, M. and Kendra, K. (2003). A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther., 10: 251-259.
136. Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Ironside, J., MacDougall, R.H., Heise, C., Randlev, B., Gillenwater, A.M., Bruso, P., Kaye, S.B., Hong, W.K. and Kim, D.H. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885.
137. Kim, J.A. (2003). Targeted therapies for the treatment of cancer. Am. J. Surg., 186: 264-268.
138. Kim, D., Martuza, R.L. and Zwiebel, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med., 7: 781-787.
139. Kirsch, D.G. and Kastan, M.B. (1998). Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol., 16: 3158-3168.
140. Klatzmann, D., Cherin, P., Bensimon, G., Boyer, O., Coutellier, A., Charlotte, F., Boccaccio, C., Salzmann, J.L. and Herson, S. (1998b). A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum. Gene Ther., 9: 2585-2594.
141. Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.L. and Philippon, J. (1998a). A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther., 9: 2595-2604.
142. Kobayashi, H., Gotoh, J., Fujie, M., Shinohara, H., Moniwa, N. and Terao, T. (1994). Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer, 57: 727-733.
143. Korpelainen, E.I. and Alitalo, K. (1998). Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol., 10: 159-164.
144. Krasnykh, V., Dmitriev, I., Mikheeva, G., Miller, C.R., Belousova, N. and Curiel, D.T. (1998). Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol., 72: 1844-1852.
145. Krieg, A.M. (2000). Immune effects and mechanisms of action of CpG motifs. Vaccine, 19: 618-622.
146. Kuball, J., Wen, S.F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D.C., Grace, M.J., Fritz, M.A., Storkel, S., Thuroff, J.W., Huber, C. and Schuler, M. (2002). Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol., 20: 957-965.
147. Kuo, C.J., Farnebo, F., Yu, E.Y., Christofferson, R., Swearingen, R.A., Carter, R., von Recum, H.A., Yuan, J., Kamihara, J., Flynn, E., D'Amato, R., Folkman, J. and Mulligan, R.C. (2001). Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA., 98: 4605-4610.
148. Kurihara, T., Brough, D.E., Kovesdi, I. and Kufe, D.W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest, 106: 763-771.
149. Kurzrock, R., Kantarjian, H.M., Druker, B.J. and Talpaz, M. (2003). Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med., 20;138: 819-830.
150. Kusumoto, M., Umeda, S., Ikubo, A., Aoki, Y., Tawfik, O., Oben, R., Williamson, S., Jewell, W. and Suzuki, T. (2001). Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother., 50: 373-381.
151. Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., Stanisic, T.H., Smith, J.A., Sullivan, J., Sarosdy, M.F. et al. (1991). A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med., 325: 1205-1209.
152. Lamont, J.P., Nemunaitis, J., Kuhn, J.A., Landers, S.A. and McCarty, T.M. (2000). A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol., 7: 588-592.
153. Lang, F.F., Yung, W.K., Sawaya, R. and Tofilon, P.J. (1999). Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery, 45: 1093-1104.
154. Lang, F.F., Bruner, J.M., Fuller, G.N., Aldape, K., Prados, M.D., Chang, S., Berger, M.S., McDermott, M.W., Kunwar, S.M., Junck, L.R., Chandler, W., Zwiebel, J.A., Kaplan, R.S. and Yung, W.K. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol., 21: 2508-2518.
155. Laurent-Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., Monges, G., Thomas, G., Bioulac-Sage, P. and Zucman-Rossi, J. (2001). Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 120: 1763-1773.
156. Le Gat, L., Gogat, K., Bouquet, C., Saint-Geniez, M., Darland, D., Van Den, B.L., Marchant, D., Provost, A., Perricaudet, M., Menasche, M. and Abitbol, M. (2003). In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Therapy, 10: 2098-2103.
157. Lee, J.M. and Bernstein, A. (1995). Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev., 14: 149-161.
158. Lee, S.S., Eisenlohr, L.C., McCue, P.A., Mastrangelo, M.J. and Lattime, E.C. (1994). Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res., 54: 3325-3328.
159. Lehtolainen, P., Taskinen, A., Laukkanen, J., Airenne, K.J., Heino, S., Lappalainen, M., Ojala, K., Marjomaki, V., Martin, J.F., Kulomaa, M.S. and Yla-Herttuala, S. (2002). Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules. J. Biol. Chem., 277: 8545-8550.
160. Lehtolainen, P., Wirth, T., Taskinen, A.K., Lehenkari, P., Leppanen, O., Lappalainen, M., Pulkkanen, K., Marttila, A., Marjomaki, V., Airenne, K.J., Horton, M., Kulomaa, M.S. and Yla-Herttuala, S. (2003). Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein. Gene Therapy, 10: 2090-2097.
161. Leissner, J., Stein, R., Hohenfellner, R., Kohl, U., Riedmiller, H., Schroder, A., Lampel, A. and Thuroff, J.W. (1999). Radical cystoprostatectomy combined with Mainz pouch bladder substitution to the urethra: long-term results. BJU. Int., 83: 964-970.
162. Leyland-Jones, B. (2002). Trastuzumab: hopes and realities. Lancet Oncol., 3: 137-144.
163. Li, H., Lu, H., Griscelli, F., Opolon, P., Sun, L.Q., Ragot, T., Legrand, Y., Belin, D., Soria, J., Soria, C., Perricaudet, M. and Yeh, P. (1998). Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy, 5: 1105-1113.
164. Li, H., Alonso-Vanegas, M., Colicos, M.A., Jung, S.S., Lochmuller, H., Sadikot, A.F., Snipes, G.J., Seth, P., Karpati, G. and Nalbantoglu, J. (1999). Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin. Cancer Res., 5: 637-642.
165. Linden, R.M., Ward, P., Giraud, C., Winocour, E. and Berns, K.I. (1996). Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA, 93: 11288-11294.
166. Liu, Y., Thor, A., Shtivelman, E., Cao, Y., Tu, G., Heath, T.D. and Debs, R.J. (1999). Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem., 274: 13338-13344.
167. Lovekin, C., Ellis, I.O., Locker, A., Robertson, J.F., Bell, J., Nicholson, R., Gullick, W.J., Elston, C.W. and Blamey, R.W. (1991). c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer, 63: 439-443.
168. Lu, P.H. and Negrin, R.S. (1994). A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol., 153: 1687-1696.
169. MacKie, R.M., Stewart, B. and Brown, S.M. (2001). Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 357: 525-526.
170. Mahasreshti, P.J., Kataram, M., Wang, M.H., Stockard, C.R., Grizzle, W.E., Carey, D., Siegal, G.P., Haisma, H.J., Alvarez, R.D. and Curiel, D.T. (2003). Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res., 9: 2701-2710.
171. Makower, D., Rozenblit, A., Kaufman, H., Edelman, M., Lane, M.E., Zwiebel, J., Haynes, H. and Wadler, S. (2003). Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res., 9: 693-702.
172. Markert, J.M., Medlock, M.D., Rabkin, S.D., Gillespie, G.Y., Todo, T., Hunter, W.D., Palmer, C. A., Feigenbaum, F., Tomatore, C., Tufaro, F. and Martuza, R.L. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7: 867-874.
173. Marshall, E. (1999). Clinical trials - Gene therapy death prompts review of adenovirus vector. Science, 286: 2244-2245.
174. Mastrangelo, M.J., Maguire, H.C., Eisenlohr, L.C., Laughlin, C.E., Monken, C.E., McCue, P.A., Kovatich, A.J. and Lattime, E.C. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther., 6: 409-422.
175. Mauceri, H.J., Hanna, N.N., Beckett, M.A., Gorski, D.H., Staba, M.J., Stellato, K.A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G.A., Sukhatme, V.P., Kufe, D.W. and Weichselbaum, R.R. (1998). Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394: 287-291.
176. McCormick, F. (2001). Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer, 1: 130-141.
177. McKie, E.A., Brown, S.M., MacLean, A.R. and Graham, D.I. (1998). Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. Neuropathol. Appl. Neurobiol., 24: 367-372.
178. Melcher, A., Todryk, S., Bateman, A., Chong, H., Lemoine, N.R. and Vile, R.G. (1999). Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res., 59: 2802-2805.
179. Melief, C.J. and Kast, W.M. (1995). T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev., 145: 167-177.
180. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K. and Yamasaki, H. (1996). Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835.
181. Miles, B.J., Shalev, M., Aguilar-Cordova, E., Timme, T.L., Lee, H.M., Yang, G., Adler, H.L., Kernen, K., Pramudji, C.K., Satoh, T., Gdor, Y., Ren, C., Ayala, G., Wheeler, T.M., Butler, E.B., Kadmon, D. and Thompson, T.C. (2001). Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther., 12: 1955-1967.
182. Minaguchi, T., Mori, T., Kanamori, Y., Matsushima, M., Yoshikawa, H., Taketani, Y. and Nakamura, Y. (1999). Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res., 59: 6063-6067.
183. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D. and Martuza, R.L. (1995). Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943.
184. Moolten, F.L. (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287.
185. Morin, P.J., Vogelstein, B. and Kinzler, K.W. (1996). Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA, 93: 7950-7954.
186. Mountain, A. (2000). Gene therapy: the first decade. Trends. Biotechnol., 18: 119-128.
187. Mukherji, B., Chakraborty, N.G. and Sivanandham, M. (1990). T-cell clones that react against autologous human tumors. Immunol. Rev., 116: 33-62.
188. Mullen, C.A., Kilstrup, M. and Blaese, R.M. (1992). Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37.
189. Mullen, C.A., Coale, M.M., Lowe, R. and Blaese, R.M. (1994). Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res., 54: 1503-1506.
190. Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C. and Kirn, D. (2001). Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy, 8: 308-315.
191. Nabel, G.J., Nabel, E.G., Yang, Z.Y., Fox, B.A., Plautz, G.E., Gao, X., Huang, L., Shu, S., Gordon, D. and Chang, A.E. (1993). Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA, 90: 11307-11311.
192. Nelson, W.G., Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Kim, M., Weber, C.E., Baccala, A.A., Goeman, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S. and Marshall, F.F. (2000). Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol., 46: S67-S72.
193. Nemunaitis, J., Holmlund, J.T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T.J., Geary, R., Dorr, A., Von Hoff, D. and Eckhardt, S.G. (1999a). Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol., 17: 3586-3595.
194. Nemunaitis, J., Fong, T., Robbins, J.M., Edelman, G., Edwards, W., Paulson, R.S., Bruce, J., Ognoskie, N., Wynne, D., Pike, M., Kowal, K., Merritt, J. and Ando, D. (1999b). Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther., 6: 322-330.
195. Nemunaitis, J., Fong, T., Burrows, F., Bruce, J., Peters, G., Ognoskie, N., Meyer, W., Wynne, D., Kerr, R., Pippen, J., Oldham, F. and Ando, D. (1999c). Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum. Gene Ther., 10: 1289-1298.
196. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S. and Kirn, D. (2000a). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res., 60: 6359-6366.
197. Nemunaitis, J., Swisher, S.G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D.D., Kemp, B.L., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M., Putnam, J.B., Richli, W.R., Shin, D.M., Walsh, G.L., Merritt, J. and Roth, J. (2000b). Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol., 18: 609-622.
198. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S. and Kirn, D. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 19: 289-298.
199. Nesbitt, J.C., Putnam, J.B., Walsh, G.L., Roth, J.A. and Mountain, C.F. (1995). Survival in early-stage non-small cell lung cancer. Ann. Thorac. Surg., 60: 466-472.
200. Nguyen, J.T., Wu, P., Clouse, M.E., Hlatky, L. and Terwilliger, E.F. (1998). Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res., 58: 5673-5677.
201. Niidome, T. and Huang, L. (2002). Gene therapy progress and prospects: nonviral vectors. Gene Therapy, 9: 1647-1652.
202. Nikitin, A.Y., Juarez-Perez, M.I., Li, S., Huang, L. and Lee, W.H. (1999). RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc. Natl. Acad. Sci. USA, 96: 3916-3921.
203. Norman, K.L., Coffey, M.C., Hirasawa, K., Demetrick, D.J., Nishikawa, S.G., DiFrancesco, L.M., Strong, J.E. and Lee, P.W. (2002). Reovirus oncolysis of human breast cancer. Hum. Gene Ther., 20;13: 641-652.
204. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H. and Folkman, J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328.
205. O'Reilly, M.S., Holmgren, L., Chen, C. and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692.
206. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R. and Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285.
207. Oertli, D., Marti, W.R., Zajac, P., Noppen, C., Kocher, T., Padovan, E., Adamina, M., Schumacher, R., Harder, F., Heberer, M. and Spagnoli, G.C. (2002). Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther., 13: 569-575.
208. Okada, S. (1998). Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology, 45 Suppl 3: 1259-1263.
209. Osanto, S., Schiphorst, P.P., Weijl, N.I., Dijkstra, N., Van Wees, A., Brouwenstein, N., Vaessen, N., Van Krieken, J.H., Hermans, J., Cleton, F.J. and Schrier, P.I. (2000). Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther., 20;11: 739-750.
210. Packer, R.J., Raffel, C., Villablanca, J.G., Tonn, J.C., Burdach, S.E., Burger, K., LaFond, D., McComb, J.G., Cogen, P.H., Vezina, G. and Kapcala, L.P. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg., 92: 249-254.
211. Paganelli, G., Grana, C., Chinol, M., Cremonesi, M., De Cicco, C., de Braud, F., Robertson, C., Zurrida, S., Casadio, C., Zoboli, S., Siccardi, A.G. and Veronesi, U. (1999). Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med., 26: 348-357.
212. Pagliaro, L.C., Keyhani, A., Williams, D., Woods, D., Liu, B., Perrotte, P., Slaton, J.W., Merritt, J.A., Grossman, H.B. and Dinney, C.P. (2003). Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J. Clin. Oncol., 21: 2247-2253.
213. Paillard, F. (1998). The search for the "best" cytokine to induce antitumor immunity. Hum. Gene Ther., 20;9: 2457-2458.
214. Pandha, H.S., Martin, L.A., Rigg, A., Hurst, H.C., Stamp, G.W., Sikora, K. and Lemoine, N.R. (1999). Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol., 17: 2180-2189.
215. Pardoll, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415.
216. Pardoll, D.M. (1998). Cancer vaccines. Nat. Med., 4: 525-531.
217. Pardoll, D.M. (1999). Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342.
218. Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O'Neil, J.D., Groene, W.S., Roberts, M.S., Rabin, H., Bamat, M.K. and Lorence, R.M. (2002). Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol., 20: 2251-2266.
219. Plautz, G.E., Yang, Z.Y., Wu, B.Y., Gao, X., Huang, L. and Nabel, G.J. (1993). Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA, 90: 4645-4649.
220. Porter, A.C. and Vaillancourt, R.R. (1998). Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene, 17: 1343-1352.
221. Quinlan, D.C., Davidson, A.G., Summers, C.L., Warden, H.E. and Doshi, H.M. (1992). Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831.
222. Rainov, N.G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 20;11: 2389-2401.
223. Raj, K., Ogston, P. and Beard, P. (2001). Virus-mediated killing of cells that lack p53 activity. Nature, 412: 914-917.
224. Ram, Z., Culver, K.W., Oshiro, E.M., Viola, J.J., DeVroom, H.L., Otto, E., Long, Z., Chiang, Y., McGarrity, G.J., Muul, L.M., Katz, D., Blaese, R.M. and Oldfield, E.H. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3: 1354-1361.
225. Ramesh, R., Marrogi, A.J. and Freeman, S.M. (1998). Tumor killing using the HSV-tk suicide gene. In: Gene Therapy and Molecular Biology, T. Boulikas (Ed.), Gene Therapy Press, Palo Alto, CA, pp. 253-263.
226. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R. and Brown, M. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy, 7: 859-866.
227. Randazzo, B.P., Bhat, M.G., Kesari, S., Fraser, N.W. and Brown, S.M. (1997). Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest Dermatol., 108: 933-937.
228. Rehn, M., Veikkola, T., Kukk-Valdre, E., Nakamura, H., Ilmonen, M., Lombardo, C., Pihlajaniemi, T., Alitalo, K. and Vuori, K. (2001). Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA, 98: 1024-1029.
229. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J. and Kirn, D. (2001). Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy, 8: 1618-1626.
230. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L.M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J. and Kirn, D. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (d11520): phase II viral, immunologic, and clinical endpoints. Cancer Res., 62: 6070-6079.
231. Rini, B.I., Selk, L.M. and Vogelzang, N.J. (1999). Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin. Cancer Res., 5: 2766-2772.
232. Rochlitz, C.F. (2001). Gene therapy of cancer. Swiss. Med. Wkly., 131: 4-9.
233. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W. and Henderson, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563.
234. Rogulski, K.R., Wing, M.S., Paielli, D.L., Gilbert, J.D., Kim, J.H. and Freytag, S.O. (2000). Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther., 11: 67-76.
235. Romano, G., Michell, P., Pacilio, C. and Giordano, A. (2000). Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem. Cells, 18: 19-39.
236. Rosenberg, S.A. (1997). Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J. Sci. Am., 3: S2-S6.
237. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C. and Topalian, S.L. (1990). Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323: 570-578.
238. Rosenberg, S.A., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. and White, D.E. (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 271: 907-913.
239. Roth, J.A., Fossella, F., Komaki, R., Ryan, M.B., Putnam, J.B., Lee, J.S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M. et al. (1994). A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst., 86: 673-680.
240. Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Ferson, D.Z., Hong, W.K., Komaki, R., Lee, J.J., Nesbitt, J.C., Pisters, K.M., Putnam, J.B., Schea, R., Shin, D.M., Walsh, G.L., Dolormente, M.M., Han, C.I., Martin, F.D., Yen, N., Xu, K., Stephens, L.C., McDonnell, T.J., Mukhopadhyay, T. and Cai, D. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med., 2: 985-991.
241. Rother, R.P., Squinto, S.P., Mason, J.M. and Rollins, S.A. (1995). Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther., 6: 429-435.
242. Rots, M.G., Curiel, D.T., Gerritsen, W.R. and Haisma, H.J. (2003). Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J. Control Release, 87: 159-165.
243. Runnebaum, I.B. and Stickeler, E. (2001). Epidemiological and molecular aspects of ovarian cancer risk. J. Cancer Res. Clin. Oncol., 127: 73-79.
244. Russell, S.J. (2002). RNA viruses as virotherapy agents. Cancer Gene Ther., 9: 961-966.
245. Sanchez-Prieto, R., Quintanilla, M., Cano, A., Leonart, M.L., Martin, P., Anaya, A. and Cajal, S. (1996). Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene, 13: 1083-1092.
246. Sandmair, A.M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynela, K., Turunen, M., Vanninen, R., Lehtolainen, P., Paljarvi, L., Johansson, R., Vapalahti, M. and Yla-Herttuala, S. (2000b). Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther., 11: 2197-2205.
247. Sandmair, A.M., Turunen, M., Tyynela, K., Loimas, S., Vainio, P., Vanninen, R., Vapalahti, M., Bjerkvig, R., Janne, J. and Yla-Herttuala, S. (2000a). Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther., 7: 413-421.
248. Sang, Q.X. (1998). Complex role of matrix metalloproteinases in angiogenesis. Cell Res., 8: 171-177.
249. Sasaki, T., Larsson, H., Kreuger, J., Salmivirta, M., Claesson-Welsh, L., Lindahl, U., Hohenester, E. and Timpl, R. (1999). Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J., 18: 6240-6248.
250. Schadendorf, D., Czarnetzki, B.M. and Wittig, B. (1995). Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma. J. Mol. Med., 73: 473-477.
251. Schakowski, F., Gorschluter, M., Junghans C., Schroff, M., Buttgereit, P., Ziske, C., Schottker, B., Konig-Merediz, S.A., Sauerbruch, T., Wittig, B. and Schmidt-Wolf, I.G. (2001). A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol. Ther., 3: 793-800.
252. Schatzlein, A.G. (2001). Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs, 12: 275-304.
253. Schiller, J.H. (2003). New directions for ZD1839 in the treatment of solid tumors. Semin. Oncol., 30: 49-55.
254. Schmidt-Wolf, I.G., Negrin, R.S., Kiem, H.P., Blume, K.G. and Weissman, I.L. (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med, 174: 139-149.
255. Schmidt-Wolf, I.G., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.G., Prange, G., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B. and Huhn, D. (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer, 81: 1009-1016.
256. Schuler, M., Rochlitz, C., Horowitz, J.A., Schlegel, J., Perruchoud, A.P., Kommoss, F., Bolliger, C.T., Kauczor, H.U., Dalquen, P., Fritz, M.A., Swanson, S., Herrmann, R. and Huber, C. (1998). A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther., 9: 2075-2082.
257. Schuler, M., Herrmann, R., De Greve, J.L., Stewart, A.K., Gatzemeier, U., Stewart, D. J., Laufman, L., Gralla, R., Kuball, J., Buhl, R., Heussel, C.P., Kommoss, F., Perruchoud, A.P., Shepherd, F.A., Fritz, M.A., Horowitz, J.A., Huber, C. and Rochlitz, C. (2001). Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J. Clin. Oncol., 19: 1750-1758.
258. Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A.G. and Barbier, N. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther., 20;10: 2325-2335.
259. Shao, N., Chai, Y.L., Shyam, E., Reddy, P. and Rao, V.N. (1996). Induction of apoptosis by the tumor suppressor protein BRCAI. Oncogene, 13: 1-7.
260. Shapiro, W.R. and Shapiro, J.R. (1998). Biology and treatment of malignant glioma. Oncology (Huntingt.), 12: 233-240.
261. Shiose, S., Sakamoto, T., Yoshikawa, H., Hata, Y., Kawano, Y., Ishibashi, T., Inomata, H., Takayama, K. and Ueno, H. (2000). Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest. Ophthalmol. Vis. Sci., 41: 2395-2403.
262. Simons, J.W., Jaffee, E.M., Weber, C.E., Levitsky, H.I., Nelson, W.G., Carducci, M.A., Lazenby, A.J., Cohen, L.K., Finn, C.C., Clift, S.M., Hauda, K.M., Beck, L.A., Leiferman, K.M., Owens, A.H., Piantadosi, S., Dranoff, G., Mulligan, R.C., Pardoll, D.M. and Marshall, F.F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537-1546.
263. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177-182.
264. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A. et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244: 707-712.
265. Sober, A.J. (1991). Cutaneous melanoma: opportunity for cure. CA Cancer J. Clin., 41: 197-199.
266. Sobol, R.E., Shawler, D.L., Carson, C., Van Beveren, C., Mercola, D., Fakhrai, H., Garrett, M.A., Barone, R., Goldfarb, P., Bartholomew, R.M., Brostoff, S., Carlo, D.J., Royston, I. and Gold, D.P. (1999). Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res., 5: 2359-2365.
267. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J.C., Hodi, F.S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K.K., Cosimi, A.B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L.K., Mulligan, R.C. and Dranoff, G. (1998). Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 95: 13141-13146.
268. Somia, N. and Verma, I.M. (2000). Gene therapy: trials and tribulations. Nat. Rev. Genet., 1: 91-99.
269. Stanton, V.P. and Cooper, G.M. (1987). Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol. Cell Biol., 7: 1171-1179.
270. Sterman, D.H., Treat, J., Litzky, L.A., Amin, K.M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J.M., Albelda, S.M. and Kaiser, L.R. (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther., 9: 1083-1092.
271. Stewart, A.K., Lassam, N.J., Quirt, I.C., Bailey, D.J., Rotstein, L.E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C.L., Moen, R.C., Gauldie, J. and Graham, EL. (1999). Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Therapy, 6: 350-363.
272. Stopeck, A.T., Hersh, E.M., Akporiaye, E.T., Harris, D.T., Grogan, T., Unger, E., Warneke, J., Schluter, S.F. and Stahl, S. (1997). Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J. Clin. Oncol., 15: 341-349.
273. Stopeck, A.T., Jones, A., Hersh, E.M., Thompson, J.A., Finucane, D.M., Gutheil, J.C. and Gonzalez, R. (2001). Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin. Cancer Res., 7: 2285-2291.
274. Strayer, D.S., Zern, M.A. and Chowdhury, J.R. (2002). What can SV40-derived vectors do for gene therapy? Curr. Opin. Mol. Ther., 4: 313-323.
275. Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P. and Lee, P.W. (1998). The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J., 17: 3351-3362.
276. Sundaresan, P., Hunter, W.D., Martuza, R.L. and Rabkin, S.D. (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J. Virol., 74: 3832-3841.
277. Sung, M.W., Yeh, H.C., Thung, S.N., Schwartz, M.E., Mandeli, J.P., Chen, S.H. and Woo, S.L. (2001). Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol. Ther., 4: 182-191.
278. Swisher, S.G., Roth, J.A., Nemunaitis, J., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Connors, D.G., El Naggar, A.K., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Mack, M., Merritt, J.A., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M., Putnam, J.B., Richli, W.R., Savin, M., Schrump, D.S., Shin, D.M., Shulkin, A., Walsh, G.L., Wait, J., Weill, D. and Waugh, M.K. (1999). Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 91: 763-771.
279. Swisher, S.G., Roth, J.A., Komaki, R., Gu, J., Lee, J.J., Hicks, M., Ro, J.Y., Hong, W.K., Merritt, J.A., Ahrar, K., Atkinson, N.E., Correa, A.M., Dolormente, M., Dreiling, L., El Naggar, A.K., Fossella, F., Francisco, R., Glisson, B., Grammer, S., Herbst, R., Huaringa, A., Kemp, B., Khuri, F.R., Kurie, J.M., Liao, Z., McDonnell, T.J., Morice, R., Morello, E., Munden, R., Papadimitrakopoulou, V., Pisters, K.M., Putnam, J.B., Sarabia, A.J., Shelton, T., Stevens, C., Shin, D.M., Smythe, W.R., Vaporciyan, A.A., Walsh, G.L. and Yin, M. (2003). Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res., 9: 93-101.
280. Szostak, M.J. and Kyprianou, N. (2000). Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol. Rep., 7: 699-706.
281. Tait, D.L., Obermiller, P.S., Redlin-Frazier, S., Jensen, R.A., Welcsh, P., Dann, J., King, M.C., Johnson, D.H. and Holt, J.T. (1997). A phase I trial of retroviral BRCAlsv gene therapy in ovarian cancer. Clin. Cancer Res., 3: 1959-1968.
282. Tait, D.L., Obermiller, P.S., Hatmaker, A.R., Redlin-Frazier, S. and Holt, J.T. (1999). Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res., 5: 1708-1714.
283. Tait, D.L., Obermiller, P.S. and Holt, J.T. (2000). Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy. Gynecol. Oncol., 79: 471-476.
284. Takahashi, T., Nau, M.M., Chiba, I., Birrer, M.J., Rosenberg, R.K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A.F. and Minna, J.D. (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science, 246: 491-494.
285. Takayama, K., Ueno, H., Nakanishi, Y., Sakamoto, T., Inoue, K., Shimizu, K., Oohashi, H. and Hara, N. (2000). Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res., 60: 2169-2177.
286. Tanaka, M., Koul, D., Davies, M.A., Liebert, M., Steck, P.A. and Grossman, H.B. (2000). MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene, 19: 5406-5412.
287. Tanaka, T., Cao, Y., Folkman, J. and Fine, H.A. (1998). Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res., 58: 3362-3369.
288. Taniguchi, T., Rigg, A. and Lemoine, N.R. (1998). Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis. Gene Therapy, 5: 1011-1013.
289. Teh, B.S., Aguilar-Cordova, E., Kernen, K., Chou, C.C., Shalev, M., Vlachaki, M.T., Miles, B., Kadmon, D., Mai, W.Y., Caillouet, J., Davis, M., Ayala, G., Wheeler, T., Brady, J., Carpenter, L.S., Lu, H.H., Chiu, J.K., Woo, S.Y., Thompson, T. and Butler, E.B. (2001). Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 51: 605-613.
290. Teh, B.S., Aguilar-Cordova, E., Aguilar, L., Mai, W., Caillouet, J., Davis, M., Vlachaki, M.T., Kadmon, D., Miles, B., Ayala, G., Thompson, T. and Butler, E.B. (2003). Late toxicity of a phase I/II trial evaluating combined radiotherapy and in-situ gene-therapy with or without hormonal therapy in the treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 57: S275.
291. Telerman, A., Tuynder, M., Dupressoir, T., Robaye, B., Sigaux, F., Shaulian, E., Oren, M., Rommelaere, J. and Amson, R. (1993). A model for tumor suppression using H-1 parvovirus. Proc. Natl. Acad. Sci. USA, 90: 8702-8706.
292. Thomas, M. and Klibanov, A.M. (2003). Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol., 62: 27-34.
293. Timme, T.L., Hall, S.J., Barrios, R., Woo, S.L., Aguilar-Cordova, E. and Thompson, T.C. (1998). Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther., 5: 74-82.
294. Tolcher, A.W. (2001). Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel. Oncologist., 6 Suppl 3: 40-44.
295. Tolcher, A.W., Reyno, L., Venner, P.M., Ernst, S.D., Moore, M., Geary, R.S., Chi, K., Hall, S., Walsh, W., Dorr, A. and Eisenhauer, E. (2002). A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res., 8: 2530-2535.
296. Topalian, S.L., Rivoltini, L., Mancini, M., Markus, N.R., Robbins, P.F., Kawakami, Y. and Rosenberg, S.A. (1994). Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465.
297. Torti, F.M. and Lum, B.L. (1984). The biology and treatment of superficial bladder cancer. J. Clin. Oncol., 2: 505-531.
298. Tran, P.L., Vigneron, J.P., Pericat, D., Dubois, S., Cazals, D., Hervy, M., DeClerck, Y.A., Degott, C. and Auclair, C. (2003). Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther., 10: 435-444.
299. Trask, T.W., Trask, R.P., Aguilar-Cordova, E., Shine, H.D., Wyde, P.R., Goodman, J.C., Hamilton, W.J., Rojas-Martinez, A., Chen, S.H., Woo, S.L. and Grossman, R.G. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther., 1: 195-203.
300. Tursz, T., Cesne, A.L., Baldeyrou, P., Gautier, E., Opolon, P., Schatz, C., Pavirani, A., Courtney, M., Lamy, D., Ragot, T., Saulnier, P., Andremont, A., Monier, R., Perricaudet, M. and Le Chevalier, T. (1996). Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J. Natl. Cancer Inst., 88: 1857-1863.
301. van Beusechem, V.W., Mastenbroek, D.C., van den Doel, P.B., Lamfers, M.L., Grill, J., Wurdinger, T., Haisma, H.J., Pinedo, H.M. and Gerritsen, W.R. (2003). Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy, 10: 1982-1991.
302. Vasey, P.A., Shulman, L.N., Campos, S., Davis, J., Gore, M., Johnston, S., Kirn, D.H., O'Neill, V., Siddiqui, N., Seiden, M.V. and Kaye, S.B. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol., 20: 1562-1569.
303. Vera, M. and Fortes, P. (2004). Simian virus-40 as a gene therapy vector. DNA Cell Biol., 23: 271-282.
304. Verma, I.M. and Somia, N. (1997). Gene therapy - promises, problems and prospects [news]. Nature, 389: 239-242.
305. Vile, R.G. and Russell, S.J. (1995). Retroviruses as vectors. Br. Med. Bull., 51: 12-30.
306. Vile, R.G., Russell, S.J. and Lemoine, N.R. (2000). Cancer gene therapy: hard lessons and new courses. Gene Therapy, 7: 2-8.
307. Villaret, D., Glisson, B., Kenady, D., Hanna, E., Carey, M., Gleich, L., Yoo, G.H., Futran, N., Hung, M.C., Anklesaria, P. and Heald, A.E. (2002). A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck, 24: 661-669.
308. Vrionis, F.D., Wu, J.K., Qi, P., Waltzman, M., Cherington, V. and Spray, D.C. (1997). The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy, 4: 577-585.
309. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hokfelt, T., Broberger, C., Porreca, F., Lai, J. L., Ren, K., Ossipov, M., Koshkin, A., Jakobsen, N., Skouv, J., Oerum, H., Jacobsen, M.H. and Wengel, J. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA, 97: 5633-5638.
310. Wang, R.F., Wang, X., Atwood, A.C., Topalian, S.L. and Rosenberg, S.A. (1999a). Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science, 284: 1351-1354.
311. Wang, R.F., Wang, X. and Rosenberg, S.A. (1999b). Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J. Exp. Med., 189: 1659-1668.
312. Warshaw, A.L. and Fernandez-del Castillo, C. (1992). Pancreatic carcinoma. N. Engl. J. Med., 326: 455-465.
313. Watson, J.C. and Ridge, J.A. (1998). Surgical management of local and regional recurrent head and neck squamous cell carcinoma. Curr. Opin. Oncol., 10: 207-212.
314. Watson, J.D., Gilman, M., Witkowski, J. and Zoller, M. (1992). Recombinant DNA. New York, Scientific American books, Inc., pp. 1-626.
315. Weill, D., Mack, M., Roth, J., Swisher, S., Proksch, S., Merritt, J. and Nemunaitis, J. (2000). Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest, 118: 966-970.
316. Wicks, I.P., Howell, M.L., Hancock, T., Kohsaka, H., Olee, T. and Carson, D.A. (1995). Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. Hum. Gene Ther., 6: 317-323.
317. Wilding, G. (1991). Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. Cancer Surv., 11: 147-163.
318. Wildner, O., Blaese, R.M. and Morris, J.C. (1999). Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res., 59: 410-413.
319. Witjes, J.A., Caris, C.T., Mungan, N.A., Debruyne, F.M. and Witjes, W.P. (1998). Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J. Urol., 160: 1668-1671.
320. Wittig, B., Marten, A., Dorbic, T., Weineck, S., Min, H., Niemitz, S., Trojaneck, B., Flieger, D., Kruopis, S., Albers, A., Loffel, J., Neubauer, A., Albers, P., Muller, S., Sauerbruch, T., Bieber, T., Huhn, D. and Schmidt-Wolf, I.G. (2001). Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum. Gene Ther., 12: 267-278.
321. Wood, C.B., Gillis, C.R. and Blumgart, L.H. (1976). A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin. Oncol., 2: 285-288.
322. Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R. and Olsen, B.R. (1999). Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J., 18: 4414-4423.
323. Yang, C.T., You, L., Yeh, C.C., Chang, J.W., Zhang, F., McCormick, F. and Jablons, D.M. (2000). Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J. Natl. Cancer Inst., 19;92: 636-641.
324. Yee, J.K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J.C. and Friedmann, T. (1994). A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA, 91: 9564-9568.
325. Yla-Herttuala, S. (1998). Gene Therapy and Brain Tumors. In: Brain Tumor Invasion: Biological, Clinical, and Therapeutic Considerations, T. Mikkelsen, R. Bjerkvig, O.D. Laerum and M.L. Rosenblum (Eds.), Wiley-Liss, pp. 435-445.
326. Yoo, G.H., Hung, M.C., Lopez-Berestein, G., LaFollette, S., Ensley, J.F., Carey, M., Batson, E., Reynolds, T.C. and Murray, J.L. (2001). Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res., 7: 1237-1245.
327. Yu, D.C., Chen, Y., Dilley, J., Li, Y., Embry, M., Zhang, H., Nguyen, N., Amin, P., Oh, J. and Henderson, D.R. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res., 61: 517-525.
328. Yuen, A.R., Halsey, J., Fisher, G.A., Holmlund, J.T., Geary, R.S., Kwoh, T.J., Dorr, A. and Sikic, B.I. (1999). Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res., 5: 3357-3363.
329. Zajac, P., Oertli, D., Marti, W., Adamina, M., Bolli, M., Guller, U., Noppen, C., Padovan, E., Schultz-Thater, E., Heberer, M. and Spagnoli, G. (2003). Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther., 14: 1497-1510.
330. Zeimet, A.G. and Marth, C. (2003). Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol., 4: 415-422.
331. Zeng, Q., Kanter, P.M., Dhir, R., Gooding, W.E., Huang, L. and Grandis, J.R. (2002). Lack of toxicity of EGFR antisense gene therapy. J. Exp. Ther. Oncol., 2: 174-186.
332. Zetter, B.R. (1998). Angiogenesis and tumor metastasis. Annu. Rev. Med, 49: 407-424.
333. Zhang, W.W., Fang, X., Mazur, W., French, B.A., Georges, R.N. and Roth, J.A. (1994). High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther., 1: 5-13.